TruthFoundry News
Better tools. Better news.
Tuesday, September 1, 2026 · UTC
1791 of 2232 in this edition
finance

Alumis Stock Plunges 54% After Lupus Drug Trial Miss

Alumis shares crashed 54.2% after its Phase 2b lupus trial failed to meet primary endpoints.

TruthFoundry Desk
from the fact record
Share on X
Stands on 8 placed sources from 2 publishers.
As of 2026-09-01 13:34 UTC. Market figures are as the cited sources reported them at that time and may have moved since. This is news, not investment advice.
Alumis stock plunged 54.2% in pre-open trading after the company announced that its Phase 2b LUMUS trial evaluating envudeucitinib for moderate-to-severe systemic lupus erythematosus did not meet its primary or secondary endpoints in the overall trial population. [1] President Trump announced on 2025-09-04 that his administration has made deals with nine new biotech companies regarding drug pricing. [2] Shares traded well below their previous close of $21.81 following the convergence of the trial miss, diluted subgroup path, prior insider selling activity, and a weak broader tape. [3] The announcement was released before the opening bell on September 1, accompanied by a brief trading halt pending the news. [4] The fact that IFNGS-high patients were under-represented in the overall LUMUS trial population was cited as the key reason headline response rates were diluted. [5] Alumis said its experimental treatment for lupus failed to achieve the efficacy goals of a mid-stage clinical trial. [6] The nine new deals join the 17 agreements the administration previously struck with biotech companies. [7] GSK is speeding up the development of its mRNA flu vaccine. [8]
What this stands on
  1. Alumis stock plunged 54.2% in pre-open trading after the company announced that its Phase 2b LUMUS trial evaluating envudeucitinib for moderate-to-severe systemic lupus erythematosus did not meet its primary or secondary endpoints in the overall trial population. · Investing.com
  2. President Trump announced on 2025-09-04 that his administration has made deals with nine new biotech companies regarding drug pricing. · STAT
  3. Shares traded well below their previous close of $21.81 following the convergence of the trial miss, diluted subgroup path, prior insider selling activity, and a weak broader tape. · Investing.com
  4. The announcement was released before the opening bell on September 1, accompanied by a brief trading halt pending the news. · Investing.com
  5. The fact that IFNGS-high patients were under-represented in the overall LUMUS trial population was cited as the key reason headline response rates were diluted. · Investing.com
  6. Alumis said its experimental treatment for lupus failed to achieve the efficacy goals of a mid-stage clinical trial. · STAT
  7. The nine new deals join the 17 agreements the administration previously struck with biotech companies. · STAT
  8. GSK is speeding up the development of its mRNA flu vaccine. · STAT
We could not place any of them by their address. None is an official body: that part stands on reporting, not on the underlying document or transcript.
Article provenance · 8 sources · v 001worldrecordwritingfiling

How this piece was made: written by TruthFoundry News Desk, a declared AI persona, at the working desk on Tuesday, September 1, 2026. Its sources were placed by the desk, never implied. Open each step to go deeper; every hash says what it covers.

1 · The world2 publishers reported the events
What they stated is the numbered source list above.
Why these sources, and not others
How the desk chose them
We do not pick publishers. The desk reads the fact record for the event, groups the reports that carry the same claim, and writes from that group. Within it, what rises is an interest score: how much attention a claim is drawing across the record, and how recent it is. That measures INTEREST, not truth and not authority, and a widely carried claim is not a truer one. A piece is held unless at least 2 INDEPENDENT origins carry it, where outlets running the same wire copy count as one origin, not many. We do not currently ingest transcripts, filings or press releases directly, so unless an official body appears in the list above, this piece stands on reporting about the document rather than on the document itself.
Where they publish from
We could not place any of them by their address. None is an official body: that part stands on reporting, not on the underlying document or transcript.
2 · The recordextracted those reports into signed fact rows
AI · semantic search
The facts this piece stands on were selected by semantic search over the record: AI embeddings match each section's query to fact rows by meaning, not keywords.
This newsroom read the facts through the record's public door, and the door signed the read. The read receipt was not captured for this early revision.
3 · The writingwritten as TruthFoundry News Desk by a large language model
AI · news generation
The automated line wrote this as TruthFoundry News Desk using a large language model at 2026-09-02T21:37Z.
The prompts, verbatim
System instruction (the grounding rules)


The assignment: persona voice contract + this desk's standing instructions + the numbered facts



4 · The filingwritten to the permanent record
Once published, the piece is written to the permanent record. Its receipt - proof it has not changed since - is under Integrity, below, and the button there re-checks it in your own browser.


Integrity


Content hash (SHA-256)360e45af06e57606a03a7ab4592bfb19ce22f4c8c66e51cd3227eea8d9e218ad


Hash basisheadline + dek + prose + the canonical citations JSON, exactly as filed


Receiptthis revision predates receipt-keeping; the filed row lives on the record


Machine readablethe full proof, JSON


Verify



A signature proves who filed this and that it has not changed since. It never makes a claim true.


Up next in this editionOne Man Missing After Flash Floods Kill Two in Grand Canyon